Awaiting development: Guidance and quality standards
Showing 1 to 10 of 391
| Title | Type |
|---|---|
| Abatacept for treating active idiopathic inflammatory myopathies [TSID10095] | Technology appraisal guidance |
| Abdominal aortic aneurysm | Quality standard |
| Acalabrutinib for treating relapsed or refractory mantle cell lymphoma [ID6389] | Technology appraisal guidance |
| Acalabrutinib with R-CHOP for untreated non-germinal centre B-cell diffuse large B-cell lymphoma [ID6614] | Technology appraisal guidance |
| Acalabrutinib with venetoclax and obinutuzumab for untreated chronic lymphocytic leukaemia [ID6156] | Technology appraisal guidance |
| Acne | Quality standard |
| Adagrasib with cetuximab for treating KRAS G12C mutation-positive advanced colorectal cancer after 1 treatment line [ID6694] | Technology appraisal guidance |
| Adalimumab for treating early Dupuytren's contracture [ID6276] | Technology appraisal guidance |
| Admilparant for treating idiopathic pulmonary fibrosis [TSID12393] | Technology appraisal guidance |
| Adrenal dysfunction | Quality standard |